DatChem Pty Ltd
June 16, 2025
Company Presentation
Medical Devices
DatChem developed technology for magnetic resonance two-dimensional COrrelated SpectroscopY protocol that records the chemical state of human tissue in vivo in a clinical scanner. The technology has data processing and recognition paradigms identifying chemical deregulation for conditions with no other diagnostic, prognostic capacity and monitors’ therapy. DatChem-Breast identifies risk of breast cancer before it develops into malignancy. DatChem-Neuro diagnoses ADHD and response to therapy.
DatChem is funded by pro-bono clinicians plus founders with investors contributing A$1.1m for development, patents & FDA application. A 510k is anticipated for DatChem-Breast in 2025.
DatChem has a 25-year relationship with an MR manufacturer on which the technology will operate.
DatChem is pre-revenue and seeks to establish a presence in the USA and EU.
DatChem’s USA patent attorney manages the portfolio of 6 patents and 12 PCT applications. Freedom to operate is available.
.jpg)
Company HQ City:
Brisbane
Company HQ State:
Queensland
Company HQ Country:
Australia
Year Founded:
2019
Lead Product in Development:
DatChem-Breast (primary)
DatChem-Neuro (primary extension)
CEO
Dr Carolyn Mountford MSc(Oxon) DPhil(Oxon) MS(Harv)
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
DatChem has patented protected products which are ready for commercialisation using an established installed base of Magnetic Resonance scanners.
When you expect your next catalyst update?
1. FDA approval for DatChem-Breast submitted mid 2024 and expected during 2025.
2. Australian TGA and EU EAM to follow within 12months of FDA approval.
What is your next catalyst (value inflection) update?
Commence commercial sites in the USA in December 2025; EU. in December 2025. Australia is operational.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}